The patent granted to vTv Therapeutics relates to use of Bach1 Inhibitors and Nrf2 Activators for “methods of treating diseases such as psoriasis, multiple sclerosis, and COPD,” according to a post to the USPTO website.
https://thefly.com/landingPageNews.php?id=2845557
https://thefly.com/landingPageNews.php?id=2845557
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.